In an AD rat model, nanosystems, particularly the PS-SLN, were much more successful in the stable delivery and distribution of nicotinamide to the brain than conventional oral nicotinamide, leading to improved neuronal counts in hippocampus subdomains being preserved, and tau hyperphosphorylation is reduced. This evidence concerns the gene MAPT and Alzheimer disease.